155 related articles for article (PubMed ID: 33150320)
1. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
Capeding MR; Sil A; Tadesse BT; Saluja T; Teshome S; Alberto E; Kim DR; Park EL; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ryu JH; Cheong I; Shim KY; Lee Y; Kim H; Lynch JA; Kim JH; Excler JL; Wartel TA; Sahastrabuddhe S
EClinicalMedicine; 2020 Oct; 27():100540. PubMed ID: 33150320
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Capeding MR; Alberto E; Sil A; Saluja T; Teshome S; Kim DR; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ham DS; Ryu JH; Lynch J; Kim JH; Kim H; Excler JL; Wartel TA; Sahastrabuddhe S
Vaccine; 2020 Jun; 38(28):4476-4483. PubMed ID: 31585725
[TBL] [Abstract][Full Text] [Related]
4. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
Carlos JC; Tadesse BT; Borja-Tabora C; Alberto E; Ylade MC; Sil A; Kim DR; Ahn HS; Yang JS; Lee JY; Kim MS; Park J; Kwon SY; Kim H; Yang SY; Ryu JH; Park H; Shin JH; Lee Y; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Reg Health West Pac; 2022 Jul; 24():100484. PubMed ID: 35664443
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
8. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine.
Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
Int J Infect Dis; 2020 Apr; 93():102-107. PubMed ID: 32004693
[TBL] [Abstract][Full Text] [Related]
9. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.
Tamrakar D; Poudel P; Thapa P; Singh S; Khadgi A; Thapa S; Tamrakar R; Shrestha A; Madhup S; Rai GK; Gupta BP; Saluja T; Sahastrabuddhe S; Shrestha R
Hum Vaccin Immunother; 2024 Dec; 20(1):2301631. PubMed ID: 38189360
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
12. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
Chaudhary S; Shah GS; Bhatta NK; Poudel P; Rai B; Uranw S; Tripathi PM; Khanal B; Ghimire A; Rai N; Gupta BP; Vemula S; Wartel TA; Sahastrabuddhe S; Saluja T
Hum Vaccin Immunother; 2023 Dec; 19(1):2203634. PubMed ID: 37128723
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
15. An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
Choi SK; Baik YO; Kim CW; Kim SK; Oh IN; Yoon H; Yu D; Lee C
Vaccine; 2021 May; 39(19):2620-2627. PubMed ID: 33849723
[TBL] [Abstract][Full Text] [Related]
16. A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity.
Koesnoe S; Medise BE; Rengganis I; Hadinegoro SR; Puspita M; Sari RM; Yang JS; Sahastrabuddhe S; Soedjatmiko ; Gunardi H; Sekartini R; Wirahmadi A; Kekalih A; Mukhi S; Satari HI; Bachtiar NS
Trop Dis Travel Med Vaccines; 2024 Feb; 10(1):3. PubMed ID: 38297337
[TBL] [Abstract][Full Text] [Related]
17. Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
Capeding MR; Tadesse BT; Sil A; Alberto E; Kim DR; Park EL; Park JY; Yang JS; Eluru JR; Jo SK; Kim H; Yang SY; Ryu JH; Park H; Shin JH; Lee Y; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
NPJ Vaccines; 2022 Jan; 7(1):12. PubMed ID: 35087084
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
19. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
